ArticleArchives of gynecology and obstetrics2018
Conservative management of endometrial cancer: a survey amongst European clinicians.
Article in Archives of gynecology and obstetrics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Chances of pregnancy and live birth among women undergoing conservative management of early-stage endometrial cancer: a systematic review and meta-analysis.Human reproduction update · 2022Pooled it
- Fertility-sparing treatments for patients with endometrial cancer: A comprehensive review.Clinical and experimental reproductive medicine · 2026Article
- Fertility-sparing treatment outcomes using immune checkpoint inhibitors in endometrial cancer patients with Lynch syndrome.Journal of gynecologic oncology · 2025Article
- Nonsurgical management of early-stage endometrial cancer due to obesity: a survey of the practice patterns of current Society of Gynecologic Oncology members.Gynecologic oncology reports · 2023Article
- Conservative management of early-stage endometrial cancer for fertility preservation: a survey study among Swedish gynecologists and gynecological oncologists.Scientific reports · 2023Article
- ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma.Facts, views & vision in ObGyn · 2023Article
- ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinomaHuman reproduction open · 2023Article
- The Metabolomic Approach for the Screening of Endometrial Cancer: Validation from a Large Cohort of Women Scheduled for Gynecological Surgery.Biomolecules · 2022Article
- Fertility-Sparing Approaches in Atypical Endometrial Hyperplasia and Endometrial Cancer Patients: Current Evidence and Future Directions.International journal of molecular sciences · 2022Review
- Review
- Hsa_Circ_0001860 Promotes Smad7 to Enhance MPA Resistance in Endometrial CancerFrontiers in cell and developmental biology · 2021Article
- Article
- The reproductive prognosis of women considering fertility preservation for early stage endometrial cancer.Archives of gynecology and obstetrics · 2020Article
- Improving response to progestin treatment of low-grade endometrial cancer.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2020Review
- Conservative treatment in early stage endometrial cancer: a review.Acta bio-medica : Atenei Parmensis · 2019Review
- National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia.American journal of obstetrics and gynecology · 2019Article
- A case of incidental endometrial adenocarcinoma diagnosed in early pregnancy and managed conservatively.Gynecologic oncology reports · 2019Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 10 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate differences and similarities in the clinical approach of young clinicians managing women with endometrial cancer (EC) conservatively.
methodsA web-based survey was carried out. A platform of the European Network of Young Gynaecological Oncologists (ENYGO) database was used. A 38-item multiple-choice questionnaire was used to evaluate current practice in fertility-sparing management of EC. The survey covered investigations, treatment options, follow-up and management of recurrence and future family planning. Descriptive statistics were used.
resultsOverall, 116 out of 650 (17.84%) ENYGO members responded to the survey. In 92 (79.3%) centres, the caseload of early stage EC treated conservatively was less than 10 per year. One hundred and seven responders (93.8%) believe that treatment with progestins could be offered in grade 1 EC without myometrial invasion, but a minority would recommend it even for grade 2 tumours with no myometrial invasion or grade 1 with superficial invasion. The diagnostic tool for establishing grade of tumour was hysteroscopy with dilatation and curettage in 64 (55%) centres. Medroxyprogesterone acetate represents the most commonly prescribed progestogen (55, 47.4%). In 78 (67.2%) centres, a repeat endometrial biopsy was offered after 3 months of treatment commencement. Recurrences are treated mostly with hysterectomy (81, 69.9%) with only a small number of responders recommending to repeat progestin treatment. Lynch syndrome is a contraindication for conservative management in half of the responders (57, 49.1%). Most clinicians agree that patients should be referred promptly for assisted reproductive techniques once complete response has been achieved (68, 58.6%).
conclusionsOur study shows that conservative management is increasingly offered to women affected by early stage EC wishing to preserve their fertility. Further studies and joint registries are required to evaluate safety and effectiveness of this approach in this probably growing number of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.